Proceedings from Koch Symposium, Understanding Signaling Pathways in Cancer
"Understanding Signaling Pathways in Cancer", a symposium presented by the Koch Institute in partnership with Cell Signaling Technology, brought together speakers from leading cancer research organizations to present their latest findings on the signaling pathways leading to cancer.
Download the "Understanding Signaling Pathways in Cancer" Koch Proceedings Guide, which provides a summation of each speaker's topic of discussion.
Joan Brugge, Ph.D., Chair of the Department of Cell Biology at Harvard Medical School, discussed her work examining pathways that allow for drug resistance of extracellular matrix-attached tumors.
Michael J. Comb, Ph.D., the founder, CEO, and Research Director of Cell Signaling Technology Inc., discussed his company’s achievements in antibody technologies that are being used to define signaling networks as a means to advance personalized medicine.
Rudolf Jaenisch, Ph.D. of the Whitehead Institute discussed the stochastic and hierarchical events that occur at the single cell level during nuclear reprogramming.
William Kaelin, M.D., The VHL Tumor Suppressor Protein: Insights into Oxygen Sensing and Cancer Metabolism
William Kaelin, M.D., of the Dana Farber Cancer Institute, discussed the connections between altered metabolism and the transformation of some cancers.
Douglas Lauffenburger, Ph.D., Multi-Scale In Vivo Systems Analysis of Cell Signaling in Inflammatory Pathologies
Douglas Lauffenburger, Ph.D. from the MIT Department of Biological Engineering discussed a systems biology engineering approach for the creation of models that describe and predict the responses of in vivo signaling pathways.
Prof. Rune Linding, Ph.D. from the Technical University of Denmark (DTU) discussed his work developing biological forecasting and the analysis of cancer kinomes using algorithms to predict the behaviors of complex signaling networks.
Benjamin Neel, Ph.D., M.D., Director of the Ontario Cancer Institute, discussed his work on the regulation of signaling networks controlling tight junction-mediated cell polarity.
David Sabatini, Ph.D., M.D. of the Whitehead Institute at MIT discussed his work defining the role of mTOR in the amino acid sensing pathway.
Jeffrey Settleman, Ph.D., the Senior Director of Discovery Oncology at Genentech, discussed his work investigating non-genetic/nonmutational drug-resistance to cancer therapeutics.
Forest M. White, Ph.D., Associate Professor of Biological Engineering of the Koch Institute at MIT discussed his work using quantitative proteomics to analyze the systemic effect of genetic mutation on phenotype.
Michael B. Yaffe, Ph.D., M.D., Harnessing Cross-Talk Between Signaling Pathways to Improve Cancer Treatment
Michael B. Yaffe, Ph.D., M.D., Professor of Biology and Biological Engineering at MIT, discussed his work examining the use of multiple anti-cancer therapeutics to dynamically re-wire signaling networks.